Entera Bio Ltd. financial data

Symbol
ENTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
Kiryat Hadassah, Minrav Building, Fifth Floor, Jerusalem, Israel
State of incorporation
Israel
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 698 % -16.4%
Debt-to-equity 19.4 % +35.6%
Return On Equity -100 % -4.89%
Return On Assets -84.1 % -0.43%
Operating Margin -71.4K % -1350%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.3M shares +26.1%
Common Stock, Shares, Outstanding 36.3M shares +26%
Entity Public Float 20.7M USD -37.1%
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 37.1M shares +28.7%
Weighted Average Number of Shares Outstanding, Diluted 37.1M shares +28.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 57K USD
Cost of Revenue 48K USD
Research and Development Expense 4.19M USD -14.5%
General and Administrative Expense 4.42M USD -21.6%
Operating Income (Loss) -8.58M USD +18.1%
Nonoperating Income (Expense) 69K USD +1050%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -8.86M USD +31.5%
Income Tax Expense (Benefit) 29K USD -78.8%
Net Income (Loss) Attributable to Parent -8.54M USD +19.6%
Earnings Per Share, Basic 0.26 USD/shares -29.7%
Earnings Per Share, Diluted 0.26 USD/shares -29.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.06M USD -0.87%
Accounts Receivable, after Allowance for Credit Loss, Current 57K USD +96.6%
Other Assets, Current 67K USD -81.1%
Assets, Current 9.6M USD -2.23%
Deferred Income Tax Assets, Net 14K USD -67.4%
Property, Plant and Equipment, Net 76K USD -37.7%
Operating Lease, Right-of-Use Asset 344K USD -25.2%
Assets 10M USD -3.93%
Accounts Payable, Current 69K USD -71.3%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 1.29M USD -30.6%
Operating Lease, Liability, Noncurrent 179K USD -43.4%
Liabilities 1.5M USD -32.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 41K USD 0%
Retained Earnings (Accumulated Deficit) -109M USD -8.54%
Stockholders' Equity Attributable to Parent 8.53M USD +3.64%
Liabilities and Equity 10M USD -3.93%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.86M USD -15.7%
Net Cash Provided by (Used in) Financing Activities 30K USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 140M shares 0%
Common Stock, Shares, Issued 36.3M shares +26%
Common Stock, Par or Stated Value Per Share 0 ILS/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.83M USD -13.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9.13M USD -0.73%
Deferred Tax Assets, Valuation Allowance 19.5M USD +10.3%
Deferred Tax Assets, Gross 19.5M USD +10.2%
Operating Lease, Liability 390K USD +329%
Depreciation 13K USD -7.14%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 454K USD
Operating Lease, Liability, Current 155K USD +10.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 184K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 184K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure -12.5%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 64K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 86K USD
Deferred Tax Assets, Operating Loss Carryforwards 17.4M USD +13%
Lessee, Operating Lease, Liability, to be Paid, Year Four 83K USD
Deferred Tax Assets, Net of Valuation Allowance 14K USD -67.4%